Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Brain Behav Immun. 2013 Apr 25;31:205–215. doi: 10.1016/j.bbi.2013.04.004

Figure 3. Genes down-regulated by infliximab over time in responders were related to apoptosis through tumor necrosis factor (TNF) and innate immune activation.

Figure 3

Infliximab (5mg/kg, n=30) was administered over 12 weeks through an indwelling catheter at baseline, 2 weeks and 6 weeks, and antidepressant response was determined as a 50% reduction in depression severity as measured by the 17-item HAM-D at any time point during the study. Genes that were up-regulated and down-regulated in responders compared to non-responders were analyzed separately at 6 hr, 24 hr, and 2 weeks to identify significant pathways that were increased or inhibited in response to infliximab that may be related to treatment response. At the earlier time points (6 and 24 hr), responders exhibited increased expression of genes related to IL-6 signaling, and decreased expression of genes related to apoptosis through TNF-related signaling pathways. At 2 weeks, gene expression profiles related to innate immune responses (antiviral and TLR signaling) were decreased in responders with respect to non-responders.